Crystal engineering yields crystals of cyclophilin D diffracting to 1.5 Å resolution: a sound basis for the support of drug discovery [PDF]
Michael Hennig+3 more
openalex +1 more source
Landscape of BRAF transcript variants in human cancer
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda+5 more
wiley +1 more source
Enhanced Mechanical Properties of Lightweight Ti<sub>65</sub>(AlCrNbV)<sub>35</sub> Medium-Entropy Alloys via Microstructure Modification Through Minor B Doping. [PDF]
Chen PS+5 more
europepmc +1 more source
Numerical methods for the yield design of civil engineering structures
Jérémy Bleyer
openalex +1 more source
Systems biology approach for enhancing limonene yield by re-engineering Escherichia coli [PDF]
Kumar Selvarajoo+4 more
openalex +1 more source
TRPM8 levels determine tumor vulnerability to channel agonists
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo+18 more
wiley +1 more source
A molecular dynamics study of the sputtering processes of beryllium species by hydrogenic plasma. [PDF]
Liptak A, Lawson KD, Hasan MI.
europepmc +1 more source
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song+11 more
wiley +1 more source
Adapting OptCouple to Identify Strategies with Increased Product Yields in Community Cohorts of <i>E. coli</i>. [PDF]
Pearcy N, Twycross J.
europepmc +1 more source
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source